Navegar

Colección

Datos Estadísticas

Artículo

Ramakrishnan, S.; Hu, Q.; Krishnan, N.; Wang, D.; Smit, E.; Granger, V.; Rak, M.; Attwood, K.; Johnson, C.; Morrison, C.; Pili, R.; Chatta, G.; Guru, K.; Gueron, G.; McNally, L.; Wang, J.; Woloszynska-Read, A. "Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer" (2017) Cell Death and Disease. 8(12)
Estamos trabajando para incorporar este artículo al repositorio
Consulte el artículo en la página del editor
Consulte la política de Acceso Abierto del editor

Abstract:

Aberrant DNA methylation observed in cancer can provide survival benefits to cells by silencing genes essential for anti-tumor activity. DNA-demethylating agents such as Decitabine (DAC)/Azacitidine (AZA) activate otherwise silenced tumor suppressor genes, alter immune response and epigenetically reprogram tumor cells. In this study, we show that non-cytotoxic nanomolar DAC concentrations modify the bladder cancer transcriptome to activate NOTCH1 at the mRNA and protein level, increase double-stranded RNA sensors and CK5-dependent differentiation. Importantly, DAC treatment increases ICN1 expression (the active intracellular domain of NOTCH1) significantly inhibiting cell proliferation and causing changes in cell size inducing morphological alterations reminiscent of senescence. These changes were not associated with β-galactosidase activity or increased p16 levels, but instead were associated with substantial IL-6 release. Increased IL-6 release was observed in both DAC-treated and ICN1 overexpressing cells as compared to control cells. Exogenous IL-6 expression was associated with a similar enlarged cell morphology that was rescued by the addition of a monoclonal antibody against IL-6. Treatment with DAC, overexpression with ICN1 or addition of exogenous IL-6 showed CK5 reduction, a surrogate marker of differentiation. Overall this study suggests that in MIBC cells, DNA hypomethylation increases NOTCH1 expression and IL-6 release to induce CK5-related differentiation. © 2017 The Author(s).

Registro:

Documento: Artículo
Título:Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer
Autor:Ramakrishnan, S.; Hu, Q.; Krishnan, N.; Wang, D.; Smit, E.; Granger, V.; Rak, M.; Attwood, K.; Johnson, C.; Morrison, C.; Pili, R.; Chatta, G.; Guru, K.; Gueron, G.; McNally, L.; Wang, J.; Woloszynska-Read, A.
Filiación:Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, United States
Department of Bioinformatics and BioStatistics, Roswell Park Cancer Institute, Buffalo, NY 14263, United States
Department of Cell Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, 31-007, Poland
Department of Medicine, Indiana University, Bloomington, IN 47405, United States
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, United States
Department of Biological Chemistry, School of Sciences, University of Buenos Aires, IQUIBICEN-CONICET Argentina, Intendente Guiraldes 2160, CABA, Buenos Aires, 1428, Argentina
Department of Medicine, University of Louisville, Louisville, KY 40292, United States
Palabras clave:beta galactosidase; decitabine; double stranded RNA; interleukin 6; messenger RNA; Notch1 receptor; protein p16; transcriptome; antineoplastic antimetabolite; azacitidine; beta galactosidase; cyclin dependent kinase inhibitor 2A; cytokeratin 5; decitabine; IL6 protein, human; interleukin 6; monoclonal antibody; NOTCH1 protein, human; Notch1 receptor; P16 protein, human; Article; cancer patient; cell proliferation; cell size; cell structure; controlled study; cytokine release; disease marker; DNA methylation; drug blood level; gene overexpression; HT-1376 cell line; human; human cell; MDA-MB-231/B02 cell line; muscle invasive bladder cancer; priority journal; T24 cell line; transcriptomics; analogs and derivatives; antagonists and inhibitors; bladder tumor; gene expression regulation; genetic epigenesis; genetics; immunology; metabolism; pathology; signal transduction; smooth muscle; treatment outcome; tumor cell line; tumor invasion; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Azacitidine; beta-Galactosidase; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Keratin-5; Muscle, Smooth; Neoplasm Invasiveness; Receptor, Notch1; Signal Transduction; Treatment Outcome; Urinary Bladder Neoplasms
Año:2017
Volumen:8
Número:12
DOI: http://dx.doi.org/10.1038/s41419-017-0024-5
Título revista:Cell Death and Disease
Título revista abreviado:Cell Death Dis.
ISSN:20414889
CAS:beta galactosidase; decitabine, 2353-33-5; azacitidine, 320-67-2, 52934-49-3; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Azacitidine; beta-Galactosidase; Cyclin-Dependent Kinase Inhibitor p16; decitabine; IL6 protein, human; Interleukin-6; Keratin-5; NOTCH1 protein, human; P16 protein, human; Receptor, Notch1
Registro:https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_20414889_v8_n12_p_Ramakrishnan

Referencias:

  • Drayton, R.M., Catto, J.W.F., Molecularmechanisms of cisplatin resistance in bladder cancer (2012) Exp. Rev. Anticancer Ther., 12, pp. 271-281
  • Von Der Maase, H., Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer (2005) J. Clin. Oncol., 23, pp. 4602-4608
  • Kaminskas, E., Farrell, A.T., Wang, Y.C., Sridhara, R., Pazdur, R., FDA drug approval summary: Azacitidine (5-azacytidine, Vidaza) for injectable suspension (2005) Oncologist, 10, pp. 176-182
  • Bender, C.M., Pao, M.M., Jones, P.A., Inhibition of DNAmethylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines (1998) Cancer Res., 58, pp. 95-101
  • Lin, X., GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells (2001) Am. J. Pathol., 159, pp. 1815-1826
  • Chiappinelli Katherine, B., Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses (2015) Cell, 162, pp. 974-986
  • Roulois, D., DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts (2015) Cell, 162, pp. 961-973
  • Ng, K.P., P53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia (2011) Leukemia, 25, pp. 1739-1750
  • Saunthararajah, Y., Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes (2015) J. Clin. Invest., 125, pp. 1043-1055
  • Fang, F., The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer (2014) Clin. Cancer Res., 20, pp. 6504-6516
  • Rampias, T., A new tumor suppressor role for the Notch pathway in bladder cancer (2014) Nat Med., 20, pp. 1199-1205
  • Maraver, A., NOTCH pathway inactivation promotes bladder cancer progression (2015) J. Clin. Invest., 125, pp. 824-830
  • Shi T-P, Xu.H., Wei J-F, Ai.X., Ma, X., Wang, B.-J., Association of low expression of Notch-1 and Jagged-1 in human papillary bladder cancer and shorter survival (2008) J. Urol., 180, pp. 361-366
  • Greife, A., Canonical Notch signalling is inactive in urothelial carcinoma (2014) BMC Cancer, 14, p. 628
  • Wang, L., Targeting Notch1 signaling pathway positively affects the sensitivity of osteosarcoma to cisplatin by regulating the expression and/or activity of Caspase family (2014) Mol. Cancer, 13, p. 139
  • Kim, M.S., Lee, W.S., Jeong, J., Kim, S.J., Jin, W., Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer (2015) Oncotarget, 6, pp. 40158-40171
  • Slattery, M.L., Lundgreen, A., Kadlubar, S.A., Bondurant, K.L., Wolff, R.K., JAK/ STAT/SOCS-signaling pathway and colon and rectal cancer (2013) Mol. Carcinog., 52, pp. 155-166
  • Wongchana, W., Palaga, T., Direct regulation of interleukin-6 expression by Notch signaling in macrophages (2012) Cell Mol. Immunol., 9, pp. 155-162
  • Rodier, F., Persistent DNA damage signaling triggers senescenceassociated inflammatory cytokine secretion (2009) Nat. Cell Biol., 11, pp. 973-979
  • Coppé, J.-P., Desprez, P.-Y., Krtolica, A., Campisi, J., The senescence-associated secretory phenotype: The dark side of tumor suppression (2010) Annu. Rev. Pathol., 5, pp. 99-118
  • Tsui, K.H., Mechanisms by which interleukin-6 attenuates cell invasion and tumorigenesis in human bladder carcinoma cells (2013) Biomed. Res. Int., 2013, p. 791212
  • Karahoca, M., Momparler, R.L., Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its doseschedule for cancer therapy (2013) Clin. Epigenet., 5, p. 3
  • Blum, W., Phase i study of decitabine alone or in combination with valproic acid in acute myeloid leukemia (2007) J. Clin. Oncol., 25, pp. 3884-3891
  • Ciamporcero, E., YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage (2016) Oncogene, 35, pp. 1541-1553
  • Wei, L., Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts (2016) Oncotarget, 7, pp. 76374-76389
  • Guichard, A., Cholera toxin disrupts barrier function by inhibiting exocystmediated trafficking of host proteins to intestinal cell junctions (2013) Cell Host Microbe, 14, pp. 294-305
  • Angello, J.C., Pendergrass, W.R., Norwood, T.H., Prothero, J., Cell enlargement: One possible mechanism underlying cellular senescence (1989) J. Cell Physiol., 140, pp. 288-294
  • Chen, Q.M., Involvement of Rb family proteins, focal adhesion proteins and protein synthesis in senescent morphogenesis induced by hydrogen peroxide (2000) J. Cell Sci., 113, pp. 4087-4097
  • Urakami, S., Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/?-catenin signaling pathway (2006) Clin. Cancer Res., 12, pp. 383-391
  • Jin, S., Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKK[alpha]/IKK [beta] (2013) Oncogene, 32, pp. 4892-4902
  • Harcourt, J.L., Offermann, M.K., Interferon-alpha synergistically enhances induction of interleukin-6 by double stranded RNA in HeLa cells (2000) Eur. J. Biochem., 267, pp. 2768-2777
  • Matsumoto, K., IL-6 induced by double-stranded RNA augments allergic inflammation via suppression of Foxp3+ T-cell/IL-10 axis (2012) Am. J. Respir. Cell. Mol. Biol., 46, pp. 740-747
  • Leonova, K.I., P53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs (2013) Proc Natl Acad. Sci. USA, 110, pp. E89-E98
  • Niemand, C., Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3 (2003) J. Immunol., 170, pp. 3263-3272
  • Rangarajan, A., Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation (2001) EMBO. J., 20, pp. 3427-3436
  • Van Batavia, J., Bladder cancers arise from distinct urothelial subpopulations (2014) Nat. Cell Biol., 16, pp. 982-991. , 981-985
  • Wielenga Mattheus, C.B., ER-stress-induced differentiation sensitizes colon cancer stem cells to chemotherapy (2015) Cell Rep., 13, pp. 489-494
  • Schumacher, U., Adam, E., Feldhaus, S., Katoh, M., Lane, D.P., Cell differentiation and chemotherapy influence p53 and Mdm2 immunoreactivity in human HT29 colon cancer cells grown in scid mice (2001) Cancer Lett., 166, pp. 215-221
  • Matei, D., Epigenetic resensitization to platinum in ovarian cancer (2012) Cancer Res., 72, pp. 2197-2205
  • Ramalingam, S.S., Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer (2010) J. Clin. Oncol., 28, pp. 56-62
  • Odunsi, K., NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer (2003) Cancer Res., 63, pp. 6076-6083
  • Liu, S., MSC transplantation improves osteopenia via epigenetic regulation of notch signaling in lupus (2015) Cell Metab., 22, pp. 606-618
  • Liu, Z., The intracellular domains of Notch1 and Notch2 are functionally equivalent during development and carcinogenesis (2015) Development, 142, pp. 2452-2463
  • Radtke, F., Raj, K., The role of Notch in tumorigenesis: Oncogene or tumour suppressor (2003) Nat. Rev. Cancer, 3, pp. 756-767
  • Fan, X., Notch1 and notch2 have opposite effects on embryonal brain tumor growth (2004) Cancer Res., 64, pp. 7787-7793
  • Hubmann, R., Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia (2002) Blood, 99, pp. 3742-3747
  • Hayashi, T., Not all notch is created equal: The oncogenic role of notch2 in bladder cancer and its implications for targeted therapy (2016) Clin. Cancer Res., 22, pp. 2981-2992
  • Ai, X., Jia, Z., Liu, S., Wang, J., Zhang, X., Notch-1 regulates proliferation and differentiation of human bladder cancer cell lines by inhibiting expression of Kruppel-like factor 4 (2014) Oncol. Rep., 32, pp. 1459-1464
  • Wang, Y., Gamma-Secretase inhibitor inhibits bladder cancer cell drug resistance and invasion by reducing epithelial-mesenchymal transition (2015) Mol. Med. Rep., 12, pp. 2821-2827
  • Groot, A.J., Regulated proteolysis of NOTCH2 and NOTCH3 receptors by ADAM10 and presenilins (2014) Mol. Cell Biol., 34, pp. 2822-2832
  • Jackson, A.L., Linsley, P.S., Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application (2010) Nat. Rev. Drug Discov., 9, pp. 57-67
  • Chen, M.F., IL-6-stimulated CD11b+ CD14+ HLA-DR-myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus (2014) Oncotarget, 5, pp. 8716-8728
  • Chen, M.F., Lin, P.Y., Wu, C.F., Chen, W.C., Wu, C.T., IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer (2013) PLoS ONE, 8, p. e61901
  • Fisher, D.T., IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells (2011) J. Clin. Invest., 121, pp. 3846-3859
  • https://www.fda.gov, US Food and Drug Administration; Zhang, Y., Cancer stem-like cells contribute to cisplatin resistance and progression in bladder cancer (2012) Cancer Lett., 322, pp. 70-77
  • Tzur, A., Moore, J.K., Jorgensen, P., Shapiro, H.M., Kirschner, M.W., Optimizing optical flow cytometry for cell volume-based sorting and analysis (2011) PLoS ONE, 6, p. e16053
  • Cerami, E., The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data (2012) Cancer Discov., 2, pp. 401-404
  • Gao, J., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal (2013) Sci. Signal., 6, p. pl1
  • Comprehensive molecular characterization of urothelial bladder carcinoma (2014) Nature, 507, pp. 315-322. , The Cancer Genome Atlas Research N

Citas:

---------- APA ----------
Ramakrishnan, S., Hu, Q., Krishnan, N., Wang, D., Smit, E., Granger, V., Rak, M.,..., Woloszynska-Read, A. (2017) . Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer. Cell Death and Disease, 8(12).
http://dx.doi.org/10.1038/s41419-017-0024-5
---------- CHICAGO ----------
Ramakrishnan, S., Hu, Q., Krishnan, N., Wang, D., Smit, E., Granger, V., et al. "Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer" . Cell Death and Disease 8, no. 12 (2017).
http://dx.doi.org/10.1038/s41419-017-0024-5
---------- MLA ----------
Ramakrishnan, S., Hu, Q., Krishnan, N., Wang, D., Smit, E., Granger, V., et al. "Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer" . Cell Death and Disease, vol. 8, no. 12, 2017.
http://dx.doi.org/10.1038/s41419-017-0024-5
---------- VANCOUVER ----------
Ramakrishnan, S., Hu, Q., Krishnan, N., Wang, D., Smit, E., Granger, V., et al. Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer. Cell Death Dis. 2017;8(12).
http://dx.doi.org/10.1038/s41419-017-0024-5